A composition comprising (i) a compound selected from the group consisting of 2-acetyl-7-chloronaphte [2,3-b] furan-4,9-dione, 2-acetyl-7-fluoro-naphtho [2,3 -b] furan-4,9-dione, 2-acetylnaphth [2,3-b] furan-4,9-dione, 2- ethylnaphto [2,3-b] furan-4,9-dione, mono- [ 1- (4,9-dioxo-3a, 4,9,9a-tetrahydro-naphtho [2,3-b] furan-2-yl) vinyl] phosphoric acid ester, and 1- (4,9-dioxo- 3a, 4,9,9a-tetrahydro-naphtho [2,3-b] furan-2-yl) vinyl ester dimethyl ester of phosphoric acid, and one of its pharmaceutically acceptable salts or solvates, and (ii) an excipient, vehicle or diluent for use to inhibit a cancer stem cell to treat a cancer in which the presence of cancer stem cells and the presence of an aberrant activity of the Stat3 pathway has been discovered, in a subject in need thereof, in which the excipient, vehicle or diluent comprises: a lipid selected from the group consisting of a phospholipid, synthetic phosphatidylcholine, natural phosphatidylcholine, sphingomyel ina, ceramide, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, cholesterol, cholesterol sulfate, and lipids conjugated to haptens and polyethylene glycol (PEG) for intravenous administration； or a waxy material selected from the group consisting of mono-, di- or triglycerides, mono- or diesters of PEG fatty acids, vitamin E conjugated to PEG, and Gelucire for oral administration； or the excipient, vehicle or diluent is in a form selected from the group consisting of a micellar emulsion, a suspension, and a suspension of nanoparticles, and further comprises human albumin for intravenous administration.Una composición que comprende (i) un compuesto seleccionado del grupo que consiste en 2-acetil-7-cloronafto[ 2,3-b]furan-4,9-diona, 2-acetil-7-fluoro-nafto[2,3-b]furan-4,9-diona, 2-acetilnafto[2,3-b]furan-4,9-diona, 2- etilnafto[2,3-b]furan-4,9-diona, mono-[1-(4,9-dioxo-3a,4,9,9a-tetrahidro-nafto[2,3-b]furan-2-il)vinil]éster del ácido fosfórico, y 1-(4,9-dioxo-3a,4,9,9a-tetrahidro-nafto[2,
